Case 2: strategies to minimize the use of calcineurin inhibitors (CNIs).
D000328:Adult; D019703:Calcineurin / Q000009:adverse effects*; D016572:Cyclosporine / Q000009:adverse effects*; D016208:Databases, Factual; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology / Q000473:pathology / Q000502:physiology*; D008297:Male; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use; D013997:Time Factors; D014481:United States; D044465:White People
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D019703:Calcineurin; D009173:Mycophenolic Acid; D016559:Tacrolimus